5-126552037-T-C
Variant summary
Our verdict is Uncertain significance. Variant got 5 ACMG points: 5P and 0B. PM2PP3_ModeratePP5
The NM_001182.5(ALDH7A1):āc.1301A>Gā(p.Tyr434Cys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000958 in 1,460,766 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_001182.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ALDH7A1 | NM_001182.5 | c.1301A>G | p.Tyr434Cys | missense_variant | 14/18 | ENST00000409134.8 | NP_001173.2 | |
ALDH7A1 | NM_001201377.2 | c.1217A>G | p.Tyr406Cys | missense_variant | 14/18 | NP_001188306.1 | ||
ALDH7A1 | NM_001202404.2 | c.1109A>G | p.Tyr370Cys | missense_variant | 12/16 | NP_001189333.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ALDH7A1 | ENST00000409134.8 | c.1301A>G | p.Tyr434Cys | missense_variant | 14/18 | 1 | NM_001182.5 | ENSP00000387123.3 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.0000239 AC: 6AN: 251196Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135768
GnomAD4 exome AF: 0.00000958 AC: 14AN: 1460766Hom.: 0 Cov.: 32 AF XY: 0.0000124 AC XY: 9AN XY: 726756
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jun 06, 2013 | p.Tyr434Cys (TAT>TGT): c.1301 A>G in exon 14 of the ALDH7A1 gene (NM_001182.3). The Tyr434Cys missense change has not been published as a mutation, nor has it been reported as a benign polymorphism to our knowledge. It was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. Although Tyrosine and Cysteine are both uncharged, polar residues, the gain of a Cysteine residue may affect disulfide bond formation in the protein. The variant alters a conserved position in the catalytic domain of the protein, and missense mutations have been reported at nearby codons. Additionally, multiple in silico algorithms predict that Tyr434Cys may be damaging to the structure/function of the protein. Therefore, based on the currently available information, Tyr434Cys is a strong candidate for a disease-causing mutation, although the possibility that it is a benign variant cannot be excluded. The variant is found in INFANT-EPI panel(s). - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 13, 2023 | Variant summary: ALDH7A1 c.1301A>G (p.Tyr434Cys) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.4e-05 in 251196 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. The variant, c.1301A>G (aka. c.1217A>G / p.Y406C), has been reported in the literature in heterozygous state (i.e. without a second allele) in a patient affected with epilepsy and Asperger's syndrome (Atli_2022), and in another patient affected with autism spectrum disorder (ASD), who had no seizure episodes (Codina-Sola_2015). These reports do not provide unequivocal conclusions about association of the variant with Pyridoxine-Dependent Epilepsy. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014, and classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Pyridoxine-dependent epilepsy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 02, 2022 | This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 434 of the ALDH7A1 protein (p.Tyr434Cys). This variant is present in population databases (rs747597620, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with ALDH7A1-related conditions. ClinVar contains an entry for this variant (Variation ID: 204848). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ALDH7A1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at